Surrozen Investor Relations Material

Surrozen Inc., established in 2015, is a clinical-stage biotechnology firm at the forefront of developing novel therapeutics designed to selectively modulate the Wnt pathway for tissue repair and regeneration. The company's innovative approach involves the creation of targeted regenerative antibodies intended to repair a wide array of tissues and restore organ function damaged by serious diseases. Surrozen leverages advanced antibody engineering techniques and a deep understanding of Wnt pathway biology across various disease settings to design tissue-specific antibodies. These antibodies have the potential to regenerate tissue in a multitude of organs and tissues, addressing diseases such as liver, intestine, retinal, lacrimal gland, lung, cornea, pancreas, skin, and many others. The company is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.